Biora Therapeutics Achieves Interim Results For Clinical Trial Of BT-600, Advancing NaviCap Platform Development
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety